Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.44 |
| ▸ | PCNA | P12004 | 1/20 | 0.44 |
| ▸ | LIG1 | P18858 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479951 | 1.00 | LTA4H (0.44) | LTA4HPCNALIG1PTGS2SCN9A | |
| Hydrochloric Acid SCHEMBL6479245 | 0.82 | MEN1 (0.50) | LTA4HPCNALIG1SCN9AP2RX3 | |
| Hydrochloric Acid SCHEMBL6479238 | 0.82 | MEN1 (0.50) | LTA4HPCNALIG1SCN9AP2RX3 | |
| SCHEMBL561974 | 0.82 | SLC7A5 (0.55) | PCNAPTGS2ADAMTS4 | |
| SCHEMBL561976 | 0.82 | SLC7A5 (0.55) | PCNAPTGS2ADAMTS4 | |
| SCHEMBL3543339 | 0.81 | LTA4H (0.58) | LTA4HPTGS2P2RX3LOXL2ADAMTS4 | |
| SCHEMBL5018913 | 0.80 | LTA4H (0.47) | LTA4HPTGS2P2RX3LOXL2ADAMTS4 | |
| Hydrochloric Acid SCHEMBL6486762 | 0.80 | KDM4E (0.48) | LTA4HPCNALIG1PTGS2SCN9A | |
| Hydrochloric Acid SCHEMBL6486766 | 0.80 | KDM4E (0.48) | LTA4HPCNALIG1PTGS2SCN9A | |
| SCHEMBL12379282 | 0.79 | LTA4H (0.60) | LTA4HPCNALIG1SCN9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | LTA4H 2227/4885PCNA 2982/4885LIG1 2189/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | LTA4H 1768/4885PCNA 3048/4885LIG1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.